EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Hernández, Gimena
• dc.contributor.author Garin Boronat, Olatz, 1979-
• dc.contributor.author Dima, Alexandra L.
• dc.contributor.author Pont Acuña, Àngels
• dc.contributor.author Martí-Pastor, Marc
• dc.contributor.author Alonso Caballero, Jordi
• dc.contributor.author Van Ganse, Eric
• dc.contributor.author Laforest, Laurent
• dc.contributor.author Bruin, Marijn de
• dc.contributor.author Mayoral, Karina
• dc.contributor.author Serra-Sutton, Vicky
• dc.contributor.author Ferrer Forés, Maria Montserrat
• dc.contributor.author ASTRO-LAB group
• dc.date.accessioned 2019-06-03T07:41:20Z
• dc.date.available 2019-06-03T07:41:20Z
• dc.date.issued 2019
• dc.description.abstract BACKGROUND: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. OBJECTIVE: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. METHODS: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes. RESULTS: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and P=.01) were of moderate magnitude with effect sizes around 0.5. CONCLUSIONS: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of this administration form.
• dc.description.sponsorship Financial support for this study was provided by the European Union Seventh Framework Programme FP7 (ASTROLAB project EC HEALTH-F5-2011-282593), Instituto de Salud Carlos III FEDER (PI12/00772), Fondo de Investigación Sanitaria, ISCIII (PI15/00449), Fondo de Investigación Sanitaria, ISCIII (PI16/00130), Fondo de Investigación Sanitaria, ISCIII (FI16/00071), ISCIII (Río Hortega, CM15/00167), and DIUE of Generalitat de Catalunya (2017 SGR 452, 2014 SGR 748). The funding agreement ensures the authors’ independence in designing the study, interpreting the data, and writing and publishing the report. The authors would like to acknowledge Aurea Martin for her help in the English editing and proofreading process, and in finalizing this manuscript.
• dc.format.mimetype application/pdf
• dc.identifier.citation Hernandez G, Garin O, Dima AL, Pont A, Martí Pastor M, Alonso J et al. EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study. J Med Internet Res. 2019 Jan 23;21(1):e10178. DOI: 10.2196/10178
• dc.identifier.doi http://dx.doi.org/10.2196/10178
• dc.identifier.issn 1438-8871
• dc.identifier.uri http://hdl.handle.net/10230/41685
• dc.language.iso eng
• dc.publisher JMIR Publications
• dc.relation.ispartof Journal of Medical Internet Research. 2019 Jan 23;21(1):e10178
• dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/282593
• dc.rights Copyright ©Gimena Hernandez, Olatz Garin, Alexandra L Dima, Angels Pont, Marc Martí Pastor, Jordi Alonso, Eric Van Ganse, Laurent Laforest, Marijn de Bruin, Karina Mayoral, Vicky Serra-Sutton, Montse Ferrer, ASTRO-LAB Group. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 23.01.2019. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/.as well as this copyright and license information must be included.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword EQ-5D-5L
• dc.subject.keyword EuroQol
• dc.subject.keyword Web-based survey
• dc.subject.keyword Asthma
• dc.subject.keyword Health-related quality of life
• dc.subject.keyword Patient-reported outcome measures
• dc.subject.keyword Validity
• dc.subject.other Qualitat de vida
• dc.subject.other Asma
• dc.title EuroQol (EQ-5D-5L) validity in assessing the quality of life in adults with asthma: cross-sectional study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion